Novo Holdings Buying Catalent in $16.5 Billion Deal
Wall Street Journal
Novo Holdings, the controlling shareholder of Danish pharmaceutical Novo Nordisk that makes weight-loss drug Wegovy, is buying pharma peer Catalent in an all-cash transaction that values the target at $16.5 billion, including debt.
https://www.wsj.com/articles/novo-holdings-buying-catalent-in-16-5-billion-deal-61efa6dc